🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

56,12 USD

Máx. histórico

149,13

4126 días

Caída desde máximo

-62,37%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-1,77%

Cierre anterior

57,13

Rango de hoy

55,97 – 57,99

Volumen hoy

2.164.741

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,10%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 2 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/10/2002 5,50 5,55 4,95 5,07 -6,46% 10,91% 142.500
03/10/2002 5,90 5,94 4,97 5,42 -11,15% 16,44% 579.000
02/10/2002 6,15 6,30 6,00 6,10 -4,39% 4,88% 133.900
01/10/2002 5,66 6,42 5,35 6,38 +10,19% 18,90% 189.300
30/09/2002 5,50 5,85 5,31 5,79 +4,14% 9,82% 247.600
27/09/2002 5,86 6,03 5,52 5,56 -5,12% 8,70% 141.300
26/09/2002 6,38 6,38 5,84 5,86 -7,42% 8,46% 273.900
25/09/2002 6,00 6,53 5,99 6,33 +5,15% 9,00% 508.800
24/09/2002 5,90 6,12 5,70 6,02 +1,52% 7,12% 212.600
23/09/2002 5,45 6,35 5,40 5,93 +4,77% 17,43% 1.409.200
20/09/2002 5,20 5,73 5,00 5,66 +4,04% 14,04% 510.200
19/09/2002 4,85 5,45 4,68 5,44 +8,80% 15,88% 351.800
18/09/2002 4,79 5,00 4,74 5,00 +2,04% 5,43% 486.200
17/09/2002 4,82 4,93 4,74 4,90 -0,20% 3,94% 361.400
16/09/2002 4,58 5,10 4,50 4,91 +14,19% 13,10% 402.500
13/09/2002 4,11 4,35 4,10 4,30 +0,70% 6,08% 105.500
12/09/2002 4,15 4,39 4,10 4,27 +0,95% 6,99% 49.100
11/09/2002 4,31 4,50 4,16 4,23 -2,76% 7,89% 103.000
10/09/2002 4,32 4,45 4,19 4,35 -1,81% 6,02% 208.800
09/09/2002 4,19 4,54 4,05 4,43 +5,48% 11,69% 263.900
06/09/2002 4,00 4,38 4,00 4,20 +5,00% 9,50% 280.300
05/09/2002 4,00 4,14 3,75 4,00 -3,38% 9,75% 85.600
04/09/2002 3,89 4,15 3,57 4,14 +6,15% 14,91% 376.100
03/09/2002 4,12 4,12 3,82 3,90 -5,80% 7,28% 177.600
30/08/2002 3,90 4,40 3,84 4,14 +7,53% 14,36% 677.100
29/08/2002 3,88 4,00 3,77 3,85 -2,28% 5,93% 378.400
28/08/2002 3,95 4,15 3,89 3,94 +7,95% 6,58% 366.600
27/08/2002 4,06 4,19 3,65 3,65 -12,05% 13,30% 229.600
26/08/2002 4,05 4,21 3,95 4,15 +0,97% 6,42% 294.700
23/08/2002 4,10 4,21 4,05 4,11 -0,96% 3,90% 149.700